LivaNova (NASDAQ:LIVN) Upgraded by StockNews.com to Buy

LivaNova (NASDAQ:LIVN) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Thursday.

LIVN has been the topic of several other reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $72.00 price target on shares of LivaNova in a report on Wednesday, March 20th. Robert W. Baird upped their price target on shares of LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a report on Thursday, February 22nd. Barclays upped their price target on shares of LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Finally, Mizuho reiterated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research report on Wednesday, March 27th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, LivaNova has an average rating of “Moderate Buy” and a consensus target price of $64.40.

LivaNova Price Performance

Shares of LIVN opened at $55.53 on Thursday. The firm has a market capitalization of $3.00 billion, a PE ratio of 173.54 and a beta of 0.89. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. LivaNova has a 1-year low of $42.75 and a 1-year high of $59.86. The company’s fifty day moving average price is $54.13 and its 200-day moving average price is $50.65.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.77 by $0.10. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The company had revenue of $310.10 million for the quarter, compared to analyst estimates of $287.65 million. During the same period in the prior year, the company earned $0.81 earnings per share. The firm’s revenue was up 12.8% on a year-over-year basis. On average, equities research analysts predict that LivaNova will post 3.01 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. acquired a new position in shares of LivaNova in the third quarter worth about $7,932,000. Kingdon Capital Management L.L.C. acquired a new position in shares of LivaNova during the 3rd quarter worth about $7,123,000. Vanguard Group Inc. raised its position in shares of LivaNova by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock worth $93,612,000 after purchasing an additional 100,133 shares during the last quarter. Barclays PLC raised its position in shares of LivaNova by 15.9% during the 3rd quarter. Barclays PLC now owns 851,870 shares of the company’s stock worth $45,047,000 after purchasing an additional 116,842 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of LivaNova during the 3rd quarter worth about $1,672,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.